SCHEMBL19829483

SCHEMBL19829483

CC(C)C1C(=O)N(c2ccccc2)N(C)C1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOX P28300 1/20 0.39
▸ LOXL3 P58215 1/20 0.39
▸ LOXL4 Q96JB6 1/20 0.39
▸ LOXL2 Q9Y4K0 1/20 0.39
▸ MAOA P21397 1/20 0.37
▸ LMNA P02545 4/20 0.36
▸ PTGS1 P23219 2/20 0.36
▸ ABCB11 O95342 1/20 0.36
▸ GSK3A P49840 2/20 0.35
▸ GSK3B P49841 2/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ FPR1 P21462 1/20 0.34
▸ OPRL1 P41146 2/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ OPRM1 P35372 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14446344 0.79 LOX (0.43) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL13415787 0.76 LMNA (0.45) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL9616703 0.76 LOX (0.41) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL9616973 0.73 LOX (0.39) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL2784650 0.73 LMNA (0.40) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL18015895 0.72 LMNA (0.36) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL13963799 0.71 ALDH1A1 (0.40) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL21694465 0.71 LMNA (0.46) LOXLOXL3LOXL4LOXL2MAOA
SCHEMBL13669801 0.71 MEN1 (0.50) MAOALMNAALDH1A1TSHRKMT2A
SCHEMBL15587183 0.70 CYP2D6 (0.45) MAOALMNACYP3A4CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180028494-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFLAMMATORY EAR DISEASES, METHOD FOR PRODUCING SAME AND METHOD FOR TREATMENT USING SAID COMPOSITION LLC KONSORTSIUM-PIK (RU) 2018-02-01 — — US disclosed
US-20180028494-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFLAMMATORY EAR DISEASES, METHOD FOR PRODUCING SAME AND METHOD FOR TREATMENT USING SAID COMPOSITION LLC KONSORTSIUM-PIK (RU) 2018-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028494-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFLAMMATORY EAR DISEASES, METHOD FOR PRODUCING SAME AND METHOD FOR TREATMENT USING SAID COMPOSITION P2RX5, P2RY4, P2RX3 LOX 1172/4885LOXL3 843/4885LOXL4 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback